Kurzfassung

A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus Rituximab plus Venetoclax (RVE) versusus Obinutuzumab (GA101) plus Venetoclax (GVE) versus Obinutuzumab plus Ibrutinib plus Venetoclax (GIVE) in fit patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17p) or TP53 mutation